1-BCP (Piperonylic acid piperidide) is a centrally active molecule that regulates the gated current of AMPA receptors. 1-BCP is a bioactive molecule that enhances memory.

Physicochemical Properties

Molecular Formula	C13H15NO3
Molecular Weight	233.26300
Exact Mass	233.105
CAS #	34023-62-6
PubChem CID	1370
Appearance	White to off-white solid powder
Density	1.256g/cm3
Boiling Point	406.9ºC at 760mmHg
Flash Point	199.9ºC
Index of Refraction	1.587
LogP	1.979
Hydrogen Bond Donor Count	0
Hydrogen Bond Acceptor Count	3
Rotatable Bond Count	1
Heavy Atom Count	17
Complexity	288
Defined Atom Stereocenter Count	0
InChi Key	BXBNADAPIHHXJQ-UHFFFAOYSA-N
InChi Code	InChI=1S/C13H15NO3/c15-13(14-6-2-1-3-7-14)10-4-5-11-12(8-10)17-9-16-11/h4-5,8H,1-3,6-7,9H2
Chemical Name	1,3-benzodioxol-5-yl(piperidin-1-yl)methanone
HS Tariff Code	2934.99.9001
Storage	Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Shipping Condition	Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity

Targets	AMPA receptor (α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor) [1][2]
ln Vitro	- 1-BCP is a centrally active modulator of AMPA receptor-gated currents. In voltage-clamped rat hippocampal neurons, 1-BCP (10, 30 μM) dose-dependently potentiated AMPA-induced inward currents, increasing the peak current amplitude by ~35% (10 μM) and ~60% (30 μM) compared with the control group (detected by patch-clamp technique) [1] - 1-BCP (1, 10, 100 μM) selectively potentiated AMPA-induced [³H]-norepinephrine release in rat hippocampal slices. At 10 μM, it increased the release by ~40% without affecting kainate or NMDA-induced neurotransmitter release (detected by radioligand assay) [2] - 1-BCP did not alter the affinity of AMPA for its receptor but prolonged the decay time of AMPA receptor-gated currents, indicating a modulatory effect on receptor desensitization or deactivation [1]
ln Vivo	- 1-BCP exhibited memory-enhancing activity in rats. Behavioral tests (passive avoidance task) showed that intraperitoneal injection of 1-BCP (5, 10 mg/kg) significantly prolonged retention latency compared with the control group, indicating improved memory consolidation [2]
Enzyme Assay	- AMPA receptor-gated current recording: Rat hippocampal neurons were cultured for 7-14 days and voltage-clamped at -60 mV using the whole-cell patch-clamp technique. 1-BCP (10, 30 μM) was preincubated with neurons for 5 minutes, followed by application of AMPA (10 μM). Inward currents were recorded, and peak amplitude and decay time were analyzed [1] - Neurotransmitter release assay: Rat hippocampal slices were prepared and preincubated with [³H]-norepinephrine for 60 minutes. Slices were then treated with 1-BCP (1-100 μM) and stimulated with AMPA (50 μM). The released [³H]-norepinephrine in the supernatant was quantified by liquid scintillation counting [2]
Cell Assay	- Hippocampal neuron culture and patch-clamp assay: Hippocampi were dissected from neonatal rats, dissociated into single neurons, and seeded on poly-L-lysine-coated coverslips. After 7-14 days of culture, neurons were used for patch-clamp recording. 1-BCP was applied to the bath solution, and AMPA-induced currents were measured to evaluate the modulatory effect [1] - Hippocampal slice neurotransmitter release assay: Rat brains were rapidly removed, and hippocampal slices (400 μm) were prepared. Slices were incubated in oxygenated Krebs-Ringer buffer, loaded with [³H]-norepinephrine, and treated with 1-BCP and AMPA. Radioactivity in the supernatant was counted to determine neurotransmitter release level [2]
Animal Protocol	- Memory enhancement model: Adult rats were randomly divided into control and 1-BCP treatment groups (5, 10 mg/kg). 1-BCP was dissolved in sterile saline and administered via intraperitoneal injection 30 minutes before the training phase of the passive avoidance task. Twenty-four hours after training, the retention test was performed, and retention latency was recorded to assess memory function [2]
References	[1]. A centrally active drug that modulates AMPA receptor gated currents. Brain Res. 1994 Feb 28;638(1-2):343-6. [2]. 1-BCP, a memory-enhancing agent, selectively potentiates AMPA-induced release in rat hippocampal slices. Neuropharmacology. 1995 Feb;34(2):141-7.
Additional Infomation	1,3-benzodioxol-5-yl(1-piperidinyl)methanone is a N-acylpiperidine. - 1-BCP is a synthetic small-molecule compound with central nervous system activity [1][2] - Its core mechanism involves selective modulation of AMPA receptors: potentiating AMPA receptor-gated currents and enhancing AMPA-induced neurotransmitter release in the hippocampus, which contributes to its memory-enhancing effect [1][2] - 1-BCP shows selectivity for AMPA receptors without affecting other glutamate receptor subtypes (kainate, NMDA), suggesting potential as a research tool for studying AMPA receptor function and a candidate for memory-related neurological disorders [1][2]

Solubility Data

Solubility (In Vitro)

DMSO : ~100 mg/mL (~428.71 mM)

Solubility (In Vivo)

Solubility in Formulation 1: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 3: ≥ 2.5 mg/mL (10.72 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.  (Please use freshly prepared in vivo formulations for optimal results.)

Preparing Stock Solutions		1 mg	5 mg	10 mg
	1 mM	4.2871 mL	21.4353 mL	42.8706 mL
	5 mM	0.8574 mL	4.2871 mL	8.5741 mL
	10 mM	0.4287 mL	2.1435 mL	4.2871 mL

*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.